ClinicalTrials.gov
ClinicalTrials.gov Menu

NOW Thai HAART Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00367731
Recruitment Status : Completed
First Posted : August 23, 2006
Last Update Posted : August 23, 2006
Sponsor:
Collaborator:
Rajavithi Biomolecular Research Center
Information provided by:
Rajavithi Hospital

Brief Summary:

After Initiation of HAART in peoples who living with HIV/AIDS in Thailand by the year 2000, rapidly expanded HAART access of national project has been promoted in 2004. Free ARVs (For CD4<200cell/cu.mm. or in symptomatic HIV with CD4<250 cell/cu.mm. )and CD4 monitoring has been available. The first-line regimen is d4T+3TC+NVP in mainly the first time (Naive) patients. CD4 response ), rate of opportunistic infection, and neurological outcomes were measured. Rate of ARV change, adverse events,treatment failure, TB co-infection rate, percent changing to EFV-based regimen or PI-based regimen were recorded.

Any Adverse Events including, Sever rash, Severe Hepatitis, Lipid abnormalities, Severe Anemia and Other, common AEs will be analysed.


Condition or disease Intervention/treatment
HIV AIDS Neurological Complications Drug: Highly Active Antiretroviral Treatment (combination of :NRTI, NNRTI,or PI)

Study Type : Observational
Enrollment : 500 participants
Observational Model: Defined Population
Observational Model: Natural History
Time Perspective: Cross-Sectional
Time Perspective: Retrospective/Prospective
Official Title: Neurological Outcomes With in THAI National HAART Program.
Study Start Date : January 2005
Study Completion Date : September 2006

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS
U.S. FDA Resources





Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   15 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • HIV/AIDS patients.
  • Age >15 years.
  • informed consent

Exclusion Criteria:

  • Not informed consent

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00367731


Locations
Thailand
Rajavithi Hospital
Bangkok, Thailand, 10400
Lumpang Hospital
Lumpang, Thailand
Sappasithiprasong Hospital
Ubonratchathani, Thailand
Sponsors and Collaborators
Rajavithi Hospital
Rajavithi Biomolecular Research Center
Investigators
Principal Investigator: Subsai Kongsaengdao, M.D. Rajavithi Hospital

ClinicalTrials.gov Identifier: NCT00367731     History of Changes
Other Study ID Numbers: RVH_CER_003
First Posted: August 23, 2006    Key Record Dates
Last Update Posted: August 23, 2006
Last Verified: August 2006

Keywords provided by Rajavithi Hospital:
HIV
AIDS
Neurological complications
HAART